…Milnacipran is a dual serotonin-norepinephrine reuptake inhibitor (SNRI) in use in Europe, Asia and Australia. Its norepineprine:serotonin effects are 3:1, in contrast to other SNRIs (e.g. venlafaxine, with a 1:30 norepineprine:serotonin ratio). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
…A longitudinal study has examined cognitive decline in 106 patients with early Parkinsons disease (mean age 61.2 years). Cognitive decline was assessed using the Mini Mental State Examination (MMSE; mean baseline 27.8) (Kandiah et al. Mov Disord 2009); epublished February 3, 2009. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
The Canadian Institutes of Health Research (CIHR, www.cihr-irsc.gc.ca), in conjunction with the province of Quebec and France, has launched a new funding program for innovative projects in Alzheimers disease research. CIHR will commit $600,000, Quebec $800,000 and France $1.1 million over the next three years to the program. A joint request for applications is currently being developed. Subscribe to read more It takes 30 seconds or login using y…
…REPORT FROM THE 2009 AAN ANNUAL MEETING – Two studies have investigated the potential benefits of rituximab, a monoclonal antibody that targets CD20 B cells, in primary- and secondary-progressive MS (PPMS, SPMS). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
…REPORT FROM THE 2009 AAN ANNUAL MEETING – A new multicentre study has found an increasing risk of Parkinsons disease with cumulative exposure to lead (Weisskopf et al. AAN 2009; abstract S23.001). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…